Adalimumab in the induction of Crohn's disease remission: Results of a Brazilian multicenter case series

Journal of Coloproctology

Volumn 31, Issue 3, 2011, Pages 233-240

  Kotze, Paulo Gustavo ^a   Vieira, Andrea ^b   Junior, Carlos Walter Sobrado ^c   Salem, Juliana Barreto ^d   da Silva Kotze, Lorete Maria ^a  

^a HOSPITAL UNIVERSITÁRIO CAJURU   (Brazil)

^b IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^c Escola de Educação Física da Polícia Militar do Estado de São Paulo   (Brazil)

^d Hospital Municipal de Urgências   (Brazil)

Author keywords

Antibodies; Crohn's disease; Monoclonal; Remission induction; Tumor necrosis factor alpha

Indexed keywords

EID: 84874723219     PISSN: 22379363     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease, evidence for and against current therapies. Aliment Pharmacol Ther 2006;25:3-12.
2. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease, seven years on. Aliment Pharmacol Ther 2006;23:451-63.
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
4. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's Disease. N Engl J Med 2004;350:876-85.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas N, Macintosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33.
6. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38.
7. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(10):52-65.
8. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, Macintosh D, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
9. Palacios NL, Mendoza JL, Taxonera C, Lana R, Ferrer MF, Díaz-Rubio M. Adalimumab induction and maintenance therapy for Crohn's disease. An open label study. Rev Esp Enferm Dig 2008;100(11):676-81.
10. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009;24:1252-7.
11. Reinisch W, Louis E, Lofberg R, Kron M, Camez A, Robinson A, et al. Influence of disease duration on adalimumab efficacy in Crohn's disease: Subanalysis of the CARE Trial. Presented at ECCO congress, Hamburg, Germany; 2009.
12. Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther 2009;29(3):273-8.
13. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-50.
14. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58(4):492-500.
15. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95.
16. Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009;30(10):977-86.
17. Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009;15(9):1308-19.